SEC Form 4 · accession 0001209191-17-046598
Tvardi Therapeutics, Inc. · TVRD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Josef Schoell
Officer — Chief Financial Officer
Period of report
Jul 26, 2017
Accepted (ET)
Jul 28, 2017 · 4:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001346830
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 26, 2017 | M | 4,000 | $2.25 | A | 50,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $2.25 | Jul 26, 2017 | M | 4,000 | D | — | Aug 14, 2018 | Common Stock | 4,000 | 0 | D |
Explanation of responses
- F1Immediately exercisable.